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Noninvasive Imaging for the Monitoring
of Progression and Regression of
Coronary Heart Disease?*
Kazuyuki Yahagi, MD, Michael Joner, MD, Renu Virmani, MDO ver the past several decades, we have madetremendous progress in understanding thepathogenesis of atherosclerotic coronary
artery disease (CAD), knowledge that has helped to
reduce morbidity and mortality. In the past few years,
the maturation of noninvasive imaging modalities,
such as computed tomography angiography (CTA)
with a resolution of 0.5 to 1.0 mm and cardiac mag-
netic resonance (CMR) with and without contrast
and a lower resolution of 1.0 to1.5 mm (with 1.5-T),
has introduced an additional dimension for predict-
ing patients at increased risk of future cardiovas-
cular events (1). Multiple randomized studies have
demonstrated the beneﬁt of statins in reducing
mortality in patients with and without CAD (2). It
has been hypothesized that low-density lipoprotein-
cholesterol (LDL-C) reduction leads to plaque modiﬁ-
cation, and small studies of intravascular ultrasound
(IVUS) and optical coherence tomography (OCT)
have shown reduction in plaque volume, inﬂamma-
tion, and necrotic core after statin treatment (3–5).*Editorials published in the Journal of the American College of Cardiology
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Yuan, PHD, served as Guest Editor for this paper.In this issue of the Journal, Noguchi et al. (6) report a
small prospective study that they conducted involving
48 patients on 12 months of pitavastatin treatment
that showed a decrease in plaque-to-myocardium
signal-intensity ratio (PMR) of high-intensity plaques
(HIPs) detected on 1.5-T noncontrast T1-weighted CMR
imaging (T1WI), especially in patients with a PMR of
$1.4. These impressive ﬁndings were accompanied by
a signiﬁcant reduction in LDL-C to <80 mg/dl as well
as a decrease in major adverse cardiac events (MACE)
compared with propensity-matched controls (2.1% vs.
16.7%). In context, MACE were deﬁned as a compo-
site of cardiac death, ST-segment elevation myocar-
dial infarction, cardiac troponin T–positive unstable
angina/non–ST-segment elevation myocardial infarc-
tion, and ischemia-driven percutaneous coronary
intervention. Acknowledging this accomplishment,
large randomized, prospective trials will be required to
further assess the capability of this innovative meth-
odology to help identify patients at risk of future
cardiovascular events.SEE PAGE 245DO PREVIOUS CLINICAL TRIALS PROVIDE
SUFFICIENT EVIDENCE THAT INITIATION
OF STATIN THERAPY EXPLAINS THE
OBSERVED BIOLOGICAL EFFECTS?
Statins have been commercially available since 1987
and are currently prescribed for an estimated 30
million people worldwide (7). Many statin trials have
been conducted for both primary and secondary
prevention of coronary heart disease. Indeed the
landmark 4S study (Scandinavian Simvastatin Sur-
vival Study) was a secondary prevention trial showing
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258a signiﬁcant reduction in total mortality and coronary
events (8). This was soon followed by a successful
primary prevention study: PROSPER (Prospective
Study of Pravastatin in the Elderly at Risk), which
enrolled individuals with a history of or risk factors
for vascular disease. Active therapy was associated
with a 24% reduction in mortality from coronary
disease (5,9). These 2 studies had a follow-up of 5.4
and 3.2 years, respectively, which is very different
from the current study of only 12 months of pit-
avastatin (4 mg/day) treatment. The current study
showed that LDL-C decreased from 125  25 mg/dl
to 70  11 mg/dl (percentage of change from
baseline: 42.1  14.1%; p < 0.001). The earlier
studies shared sufﬁcient power and duration to
detect meaningful mortality differences, whereas the
current study was not appropriately sized nor
designed to prospectively assess risk stratiﬁcation of
patients with CAD. This study’s main inadequacy is
its use of a propensity score–matched control group in
the absence of statin treatment, which cannot replace
prospective, randomized trials. Today, the standard
of care for patients with CAD is statin therapy for all,
and studies without statin treatment are no longer
considered ethical to perform; therefore, we have to
assess low- versus high-dose statin therapy.
Initial animal studies have contributed enormously
to our understanding of the response to statin treat-
ment (10) by showing a deﬁnite reduction in plaque
area and macrophage inﬁltration with an increase in
ﬁbrous tissue (11). Later mechanistic studies demon-
strated that statins quench nuclear factor kappa B
while increasing peroxisome proliferator–activated
receptor alpha and gamma activation, processes that
affect inﬂammation and angiogenesis (12). Overall,
the hypolipidemic effects of statins are weak in mice
because of differences in circulating lipoproteins,
whereas the response to statins in the Watanabe
heritable hyperlipidemic (WHHL) animal model may
be more representative of human plaques (13). In this
context, a study in WHHL rabbits treated with statins
over a 1-year period showed a 20% reduction in
circulating cholesterol and stabilization of coronary
plaques. This was the end product of a decrease in the
ratio of foam cells to macrophages and extracellular
lipid content as well as an increase in the stabilization
components of collagen and smooth muscle cells (13).
In the current study (6), the primary endpoint at
12 months was a change in the PMR value of HIP,
which was accompanied by a decrease in the total and
percentage of atheroma volume, total low attenuated
plaque (LAP) volume of <30 Hounsﬁeld units, and
percentage of LAP volume on CTA compared with a
matched control group. On the contrary, propensity-matched controls showed the opposite trends.
Moreover, there were a signiﬁcant lowering of LDL-C
and a reduction in high-sensitivity C-reactive protein,
both of which correlated with the percentage of
change in the PMR. The underlying mechanism for
this effect is not well understood, especially given the
relatively short 12-month follow-up. Similarly, a small
OCT study (resolution of 10 to 15 mm) of 35 patients
presenting with unstable angina and untreated dys-
lipidemia who were then treated with 5 or 20 mg
atorvastatin revealed a signiﬁcant increase in ﬁbrous
cap thickness, a reduction in lipid core arc, and a
reduction in macrophage intensity within 12 months
but only for those treated with the high-dose statin
(4). Reductions in circulating LDL-C were 69 mg/dl
and 78 mg/dl for high- and low-dose atorvastatin,
respectively (4). Despite these remarkable accom-
plishments, we have to bear in mind that these are
selected studies with imaging surrogate endpoints
and insufﬁcient power to make meaningful recom-
mendations without seeing hard clinical outcomes or
large prospective, randomized trials. Indeed, some of
these ﬁndings may arise from chance alone and may
be disallowed in large prospective studies.
In a 2009 report, the same authors (14) showed that
HIP detected by noncontrast T1WI is associated with
positive coronary remodeling and mirrored by low
density on CTA and ultrasound attenuation. In a sub-
sequent paper, Noguchi et al. (15) reported that plaques
with a PMR $1.4 were signiﬁcant independent pre-
dictors of coronary events within 55 months of follow-
up. The event rate (25.8%) was signiﬁcantly higher in
patients with a PMR $1.4 compared with patients with
a PMR of 1.0 to 1.4 (event rate of 8.4%) and was lowest
(1.1%) in thosewith a PMR<1.0 (15). The best predictors
of coronary events were age, male sex, glycosylated
hemoglobin, proven CAD, and a PMR $1.4 (15). How-
ever, the positive predictive value for a future coronary
event (PMR: $1.4 vs. <1.4) was low (26%), but sensi-
tivity, speciﬁcity, and negative predictive value were
high (80%, 77%, and 87%, respectively). On the other
hand, Motoyama et al. (16) showed that the diagnostic
accuracy of CT-derived plaque characteristics such as
positive remodeling, LAP (<30 Hounsﬁeld units), and
spotty calciﬁcation demonstrated a high positive pre-
dictive value, and the absence of all 3 had a high
negative predictive value for culprit plaques associ-
ated with acute coronary syndrome (ACS).
Sudden coronary death attributed to plaque
rupture, as we described in an autopsy study in 1997
(17), showed the highest frequency of vulnerable
plaques (thin-cap ﬁbroatheromas [TCFAs]) deﬁned as
ﬁbrous cap thickness of <65 mm with macrophage
inﬁltration and an underlying large necrotic core
FIGURE 1 Plaque Progression or Regression?
Plaques rich in necrotic core (NC) with a thin ﬁbrous cap (a thin-cap ﬁbroatheroma, arrows)
are considered vulnerable plaque. After stain therapy, these are more likely to regress with
a decrease in lipid content (NC) and an increase in ﬁbrous tissue (thick-cap ﬁbroatheroma),
with or without an intensiﬁcation in calciﬁcation. On the other hand, in the absence of
statin therapy, thin-cap ﬁbroatheromas are more likely to progress and lead to plaque
rupture (arrowheads indicate rupture site). Th ¼ luminal thrombus.
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259(usually >25% of plaque area) (18) (Figure 1). Imaging
surrogates of vulnerable lesions are best represented
by lipid-rich plaque on CTA, HIP by CMR, and echo-
lucent plaque by echocardiography. It is therefore not
surprising that only invasive imaging technologies,
such as OCT with its higher resolution, best replicate
lesions with histopathological changes consistent
with lesion vulnerability.
Intraplaque hemorrhage is well known as a major
contributor to necrotic core enlargement. We have
shown that hemorrhage into a plaque is commonly
observed in lesions with early and late necrotic cores
and TCFAs (19). In coronary lesions from sudden
death victims, intraplaque hemorrhage was identiﬁed
by immunostaining against glycophorin A, a selective
erythrocyte membrane protein, which was observed
with increasing intensity as the necrotic core enlarged
(19). Therefore, HIP on T1WI may best represent
intraplaque hemorrhage. However, hemorrhage in
carotid endarterectomy specimens is far more
frequent compared with coronary arteries; therefore,
HIP may represent the presence of lipid, with or
without hemorrhage. Although a study by Yuan et al.
(20) showed high sensitivity and speciﬁcity of intra-
plaque hemorrhage with HIP on T1WI, hemorrhage
was later identiﬁed by histology as intact red cells. It
is therefore unclear in this study whether hemorrhage
actually occurred during surgical removal of the pla-
que, whereas the study by Kolodgie et al. (19) dis-
regarded intact red cells and focused on remnants of
red blood cell membranes, which also represent a
viable source of free cholesterol in the necrotic core.
In a recent prospective study of 697 patients who
presented with ACS and successfully underwent
percutaneous coronary intervention, 3-vessel intra-
vascular imaging was performed using virtual histol-
ogy (VH)-IVUS and followed for 3.4 years to monitor
the development of nonculprit-related MACE. The
adverse event rate was 18.2% if the TCFA had >70%
plaque burden and minimal luminal area #4 mm2 at
follow-up (21). This is the earliest large prospective
study showing that future ACS can arise from plaques
with characteristics of TCFAs and are accompanied
by a high plaque burden and a small lumen area.
A similar, albeit, smaller study in the same year
conﬁrmed the previous results showing that VH-TCFA
(hazard ratio [HR]: 8.16; p ¼ 0.007), plaque burden
>70% (HR: 7.48; p < 0.001), and minimal luminalarea <4 mm2 (HR: 2.91; p ¼ 0.036) were associated
with total MACE (22). This reinforces the conclusion
that TCFAs of certain dimensions do lead to future
events, whereas the current study by Noguchi et al.
(6) shows that high-dose statins can change plaque
morphology and prevent future events.
In summary, the current study is tantalizing but
not conﬁrmatory. There are recognized pitfalls
involving small cohorts together with further limita-
tions of CMR because coronary arteries are barely
visualized by this low-resolution modality. Never-
theless, PMR values may eventually prove to be a
valuable surrogate for high-risk atherosclerotic pla-
ques. Moreover, noninvasive CMR may be the future
for risk stratiﬁcation of CAD patients because the
level of radiation exposure is reduced compared
with CT.
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